Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis Brady Granier, President of BioCorRx, Inc., and CEO of BioCorRx Pharmaceuticals, ...
Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback